How Generic Ozempic Could Reshape the Healthcare Economy

https://www.reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/

JEC Scarborough — About every one in ten Canadians above the age of one suffers from diabetes (“Diabetes”, 2025). Symptoms of diabetes include weight loss, mood changes, and fatigue (“Diabetes”, 2025). However, thanks to medical advancements, diabetes has become more manageable through various technologies. One of the most notable innovations was the creation of Ozempic, a drug that stimulates the pancreas by pushing glucose out of the bloodstream (Catanese, 2024).

As of 2026, an estimated 3 million Canadians were taking Ozempic or a similar semaglutide or GLP-1 drug (Ireland, 2026), with the majority of users having some form of diabetes (Mott and Arif, 2024). Thanks to its popularity, Ozempic gained $18 billion in revenue in 2024 alone (Fourreau, 2025). In May 2026, the federal government announced the approval of generic forms of Ozempic. This new approach to healthcare will have significant effects on the economy.

The Benefits of Generic Ozempic

Since the introduction of the semaglutide market in Canada, Ozempic has dominated without any real competition. However, with Health Canada’s approval of generic competitors from companies such as Dr. Reddy’s and Apotex, changes may be introduced to the market! As more firms enter the industry, the overall supply of such drugs increases. According to the law of supply and demand, an increase in supply leads to lower prices for consumers. This means patients who rely on semaglutide treatments may soon have access to more affordable alternatives (Health Canada, 2026).

The impact of varied treatments extends beyond individual consumers. Prior to the approval of generic variations of GLP-1, Novo Nordisk’s Ozempic held a dominant position in the Canadian market. This led to the company having significant pricing power. However, the entry of generic manufacturers shifts the market away from a near-monopoly structure, leading to a much more diversified market resembling something closer to monopolistic competition. In June 2026, the average price of 2 mg of Ozempic was $252.98, while the average price of 2 mg of generic Ozempic was $88.00 (“Compare GLP-1 Medication Prices Across Canadian Pharmacies”, 2026).

As more companies are approved, producers must fight to have a greater influence over consumers by lowering prices and improving quality, giving consumers much more choice regarding purchasing the versions of the goods that best suit their needs. Canada currently spends hundreds of millions of dollars annually on semaglutide-based medications, with Ozempic itself accounting for roughly $807 million in public drug spending during 2024 (Canadian Institute for Health Information [CIHI], 2025). Generic manufacturers can introduce low-cost alternatives, which in turn reduce costs and burdens for healthcare providers and insurance companies, allowing the government to allocate resources to other matters while ensuring patients receive proper treatment.

The Consequences of Generic Ozempic

Ozempic creates financial strain because it requires long-term use to maintain results. Although Ozempic is used for medical purposes, it is also used for weight loss. To maintain low weight, consumers must continuously inject Ozempic. If one decides to stop using the medication, results from previous treatments would be lost. Eventually, costs accumulate over time, with yearly prices averaging between $2400 and $3600 (Aungst and Morris, 2026). This is an example of a ‘Nokia trap’. This term is used to describe a consumer’s overdependency on a solution, resulting in continuous purchasing of the same product to avoid losing its benefits.

Sadly, the popularity of Ozempic-adjacent drugs has also contributed to unrealistic body image expectations. Semaglutides have been used by individuals to pursue weight loss through rapid, chemical methods rather than focusing on healthy lifestyle changes. This, in turn, reinforces artificial beauty, impacting various industries, including the content creation and beauty sectors.

Additionally, the product, packaging, and disposal of millions of single-use injection pens contribute to medical waste (Adey, 2026). They contribute significantly to the growing volume of medical waste generated by healthcare systems, and unlike general household waste, medical plastics and pharmaceutical delivery devices often require specialized disposal processes. This increases the strain on healthcare waste management systems and raises environmental concerns related to incineration and plastic accumulation.

Overall, while Ozempic generic drugs offer significant benefits, their economic cost, and broader social consequences should be carefully considered before making it an integral part of the wider weight loss and health industry.

Should We Accept This Decision?

Ultimately, Canada’s approval of various semaglutides will benefit Canadians, healthcare providers, and the Canadian economy. Prices are expected to drop due to the heightened competition. At the time of writing, this prediction is being proven, as Ozempic prices went down in May 2026 (Hannay, 2026). The increased supply of such drugs will provide consumers with cheaper options across multiple companies, preventing overreliance on Ozempic. A diversified market will also allow for more personalized treatment plans, allowing patients to choose a medication that will better suit their lifestyle.

Although this decision comes with many health risks, it can be argued that these side effects can be managed through lifestyle changes or medical supervision. Another major concern is the delay in approval across provincial public health insurance systems. However, after some time has passed, Ozempic generics will likely be legalized in all provinces, lowering costs for Canadians across the country. Moreover, GLP-1 drugs have been used to indirectly body-shame young women. To solve this issue, it is important to look at stopping factors that contribute to body insecurity. This solution would prevent the use of Ozempic for cosmetic purposes without compromising treatments for diabetes patients.

Conclusion

In conclusion, the federal government’s approval of Ozempic-related drugs will revolutionize how the healthcare economy functions, putting more power into the hands of consumers. By increasing competition for semaglutides, companies are pressured to maintain low prices while improving their product quality, making these drugs more accessible for all.

Works Cited

Alberta Blue Cross. (2026). GLP-1 spending analysis. Alberta Blue Cross. https://www.ab.bluecross.ca/index.php.

Apotex Inc. (2026, May 14). Apotex launches Apo-Semaglutide Injection in Canada. Apotex Inc. https://www.apotex.com/global/news/news-release/2026/05/14/apotex-launches-apo-semaglutide-injection-a-generic-equivalent-of-ozempic-in-canada.

Bloomberg. (2026, May 28). Apotex Health files preliminary prospectus for initial public offering of shares. BNN Bloomberg. https://www.bnnbloomberg.ca/business/company-news/2026/05/28/apotex-health-files-preliminary-prospectus-for-initial-public-offering-of-shares/.

Canadian Institute for Health Information. (2026). Canada’s public drug program spending reaches $18.4 billion in 2023, medications like Ozempic driving cost. Canadian Institute for Health Information. https://www.cihi.ca/en/news/canadas-public-drug-program-spending-reaches-184-billion-in-2023-medications-like-ozempic-driving.

Canadian Institute for Health Information. (2026, March 10). Ozempic the leading medication driving growth in public drug spending in Canada. CIHI. https://www.cihi.ca/en/news/ozempic-the-leading-medication-driving-growth-in-public-drug-spending-in-canada.

Catanese, L. (2024, February 5). GLP-1 diabetes and weight-loss drug side effects: “Ozempic face” and more. Harvard Health Publishing. https://www.health.harvard.edu/healthy-aging-and-longevity/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more.

Davies, M, et al. (2021, February 10). Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183.

Dr. Reddy’s Laboratories Ltd. (2026, May 16). Dr. Reddy’s launches Semaglutide Injection in Canada. Business Wire. https://www.businesswire.com/news/home/20260515689507/en/Dr.-Reddys-Laboratories-Launches-its-Generic-Semaglutide-Injection-in-Canada.

Food and Drug Administration. (2025, January). Ozempic (Semaglutide) Prescribing Information and Safety Label. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf.

Fourreau, V. (2025, November 26). Chart: Ozempic Now a Major Player on the Diabetes Drug Market. Statista. https://www.statista.com/chart/35435/revenue-diabetes-medication/?srsltid=AfmBOopEnpJdygZI3y3OZeykY_2jSfYZKMZ1BVie-e0AVHGHN95WI1o3.

Government of Canada. (2025, November 21). Diabetes: Overview. Government of Canada. https://www.canada.ca/en/public-health/services/diseases/diabetes.html.

Hannay, C. (2026, May 27). Ozempic maker cuts price as generic versions hit pharmacy shelves. Globe and Mail. https://www.theglobeandmail.com/business/economy/article-ozempic-price-brand-name-drug-generic-semaglutide-weight-loss/.

Health Canada. (2026, April 28). Canada becomes the first G7 country to approve a generic version of semaglutide. Government of Canada. https://www.canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html.

Health Canada. (2026, May 1). Canada approves second generic semaglutide, becoming the first G7 country to do so. Government of Canada. https://www.canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html.

Ireland, N. (2026, March 4). 3 million Canadians use GLP-1 drugs. Survey says that’s changing their appetites — and habits. Canadian Broadcasting Corporation. https://www.cbc.ca/news/health/canadians-glp1-ozempic-mounjaro-9.7114197.

La Grassa, J. (2026, May 29). Generic Ozempic is now about $100 a month across the country. Canadians are taking note. Canadian Broadcasting Corporation. https://www.cbc.ca/news/health/generic-ozempic-canada-semaglutide-9.7215850.

Mott, S. and Arif, H. (2024, March 7). Roughly 1M Canadians use Ozempic, similar drugs for weight loss, diabetes: study. CTV News. https://www.ctvnews.ca/atlantic/article/roughly-1m-canadians-use-ozempic-similar-drugs-for-weight-loss-diabetes-study/.

National Library of Medicine. (2022, October). Semaglutide Drug Monograph. National Library of Medicine. www.ncbi.nlm.nih.gov/books/NBK602627/.

Novo Nordisk. (2026, April). Ozempic (Semaglutide) Prescribing Information. Novo Nordisk. https://www.ozempic.com/prescribing-information.html.

Ontario Ministry of Health. (2026). Ontario Drug Benefit Formulary/Comparative Drug Index. Government of Ontario. https://www.ontario.ca/document/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0.

Pan-Canadian Pharmaceutical Alliance. (2026). Generic drug pricing framework. Pan-Canadian Pharmaceutical Alliance. https://pcpa-app.ca/negotiations/drug-categories/generic-drugs.

Province of Alberta. (2026). Alberta Drug Benefit List. Government of Alberta. https://idbl.ab.bluecross.ca/idbl/load.do.

Rubino, D. et al. (2021, March 23). Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Obesity. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2777886.

Siam, N. H. et al. (2024, December 11). Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC11683709/.

U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. (2025). Generic drug market competition and supply analysis. U.S. Department of Health and Human Services.

U. S. Department of Health and Human Services. (2022, March). GLP-1 Receptor Agonists: Diabetes Medicines. U.S. Department of Health and Human Services. https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments.

Written by: Naomi Chan, Prayas Mohanty, and Miranda Chen.